Merck – media

Merck’s New Digital Diabetes Coaching to Educate and Manage Patients

Merck & Co. and Healthy Interactions alliance’s Map4health, a new digital and mobile service catering to diabetes patients, is designed for connecting patients with doctors to educate and help them between clinic visits.
- Source: FiercePharma
- 1,177
- August 31, 2018
Company Insight diabetes Merck mHealth
Researchers Move Forward In Their Search for Non-Addictive Analgesic

Wake Forest School of medicine researchers together with the National Institute on Drug Abuse are striving to combat the country’s opioid crisis and could possibly have developed an analgesic that is harmless and non-addictive in an animal model.
- Source: MedicalXpress
- 791
- August 31, 2018
Company Insight Merck opioid
Healthy Interactions and Merck roll out digital diabetes management, counselling software

Merck and Healthy Interactions, a healthcare firm for people that provides digital and personal solutions for management and education of chronic illnesses, jointly started a diabetes management and engagement platform which encourages personal counselling programs.
- Source: MobiHealthNews
- 1,026
- August 22, 2018
Company Insight digital health Merck
HitGen and Merck Collaborates For DNA Library Screening

HitGen and Merck have updated their licensing agreement to a full-fledged drug discovery collaboration in order to screen DNA-encoded libraries for new small-molecule assets.
- Source: FierceBiotech
- 1,026
- August 8, 2018
biotech China Company Insight Merck
Merck Presents 96-Week Doravirine HIV Data Three Months before PDUFA Date

96-week data on doravirine, Merck’s HIV drug, was posted by the drugmaker recently. Merck expects it to outrun drugs like Bristol-Myers Squibb’s Sustiva in combination regimens and antiretroviral drugs from AbbVie and Johnson & Johnson in viral suppression.
- Source: FierceBiotech
- 906
- July 27, 2018
HIV Merck Researches
FDA Anounces Restricted use of Keytruda & Tecentriq Against Bladder Cancer

Keytruda is now allowed only for the patients whose tumor expression levels of the biomarker PD-L1 meet a combined positive score of 10 or higher. Tecentriq can only be used where PD-L1 immune cells can cover only 5% or more of their tumor area.
- Source: FiercePharma
- 783
- June 26, 2018
bladder cancer Company Insights Merck Roche
One More Approval for Merck’s Keytruda

On Wednesday, a day after Keytruda got the thumbs up for cervical cancer, the drug was approved for treatment of a rare form of non-Hodgkins lymphoma patients who cancer returned after at least two previous treatment lines. Last year, Keytruda also got an indication for classical Hodgkin lymphoma.
- Source: Fierce Pharma
- 723
- June 15, 2018
cancer Merck New Approvals non-Hodgkin lymphoma
Zhifei Biological Products, the 2018 Richest Drug Maker in China

Merck & Co, developer of Gardasil and Gardasil 9 which recently got approved by Chinese authorities, have earned millions of dollars for their Zhifei Biological Products. It has also spurred two Chinese families into Bloomberg’s ranking of the world richest people.
- Source: Ddu
- 682
- June 1, 2018
China Market Views Merck
New Cancer Drug Of Eisai And Merck Stalled By FDA

In a major setback for Eisai and Merck & Co, the FDA has stalled the roll-out of Lenvima as a treatment for earlier untreated liver cancer patients. Big things were expected by Merck & Co when Eisai’s Lenvima was scheduled to be launched in March. Merck has agreed to shell out USD 5.8 billion on half of the liver cancer’s drug sales.
- Source: Ddu
- 691
- May 28, 2018
FDA Merck New Approvals
Mercks to Lead Squamous Lung Cancer Treatment With Keytruda

Pharma giant Merck & Co. revealed Keytruda had perfectly completed its final-stage research on the drug for previously untreated patients with skin cancer, who represent about 25% to 30% of the overall market.
- Source: Ddu
- 650
- May 24, 2018
cancer Company Insight Merck

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.